IL144228A0 - Use of apoptosis inducing agents in the treatment of (auto) immune diseases - Google Patents
Use of apoptosis inducing agents in the treatment of (auto) immune diseasesInfo
- Publication number
- IL144228A0 IL144228A0 IL14422800A IL14422800A IL144228A0 IL 144228 A0 IL144228 A0 IL 144228A0 IL 14422800 A IL14422800 A IL 14422800A IL 14422800 A IL14422800 A IL 14422800A IL 144228 A0 IL144228 A0 IL 144228A0
- Authority
- IL
- Israel
- Prior art keywords
- auto
- immune diseases
- treatment
- inducing agents
- apoptosis inducing
- Prior art date
Links
- 208000026278 immune system disease Diseases 0.000 title abstract 3
- 230000006907 apoptotic process Effects 0.000 title 1
- 230000001939 inductive effect Effects 0.000 title 1
- 102000010565 Apoptosis Regulatory Proteins Human genes 0.000 abstract 1
- 108010063104 Apoptosis Regulatory Proteins Proteins 0.000 abstract 1
- 230000001640 apoptogenic effect Effects 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000001476 gene delivery Methods 0.000 abstract 1
- 230000006882 induction of apoptosis Effects 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 210000002437 synoviocyte Anatomy 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99200056 | 1999-01-11 | ||
| PCT/NL2000/000013 WO2000041497A2 (fr) | 1999-01-11 | 2000-01-10 | Utilisation d'agents induisant l'apoptose, dans le traitement de maladies (auto)immunes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL144228A0 true IL144228A0 (en) | 2002-05-23 |
Family
ID=8239795
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL14422800A IL144228A0 (en) | 1999-01-11 | 2000-01-10 | Use of apoptosis inducing agents in the treatment of (auto) immune diseases |
| IL144228A IL144228A (en) | 1999-01-11 | 2001-07-10 | Use of apoptosis inducing agents in the preparation of a medicament for the treatment of (auto) immune diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL144228A IL144228A (en) | 1999-01-11 | 2001-07-10 | Use of apoptosis inducing agents in the preparation of a medicament for the treatment of (auto) immune diseases |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20050271624A1 (fr) |
| EP (1) | EP1143994B1 (fr) |
| JP (1) | JP2003500336A (fr) |
| AT (1) | ATE244014T1 (fr) |
| AU (1) | AU3083500A (fr) |
| CA (1) | CA2359392A1 (fr) |
| DE (1) | DE60003632T2 (fr) |
| DK (1) | DK1143994T3 (fr) |
| EA (1) | EA200100770A1 (fr) |
| ES (1) | ES2202039T3 (fr) |
| HU (1) | HUP0200552A2 (fr) |
| IL (2) | IL144228A0 (fr) |
| MX (1) | MXPA01006998A (fr) |
| NO (1) | NO20013397L (fr) |
| PT (1) | PT1143994E (fr) |
| TR (1) | TR200102713T2 (fr) |
| WO (1) | WO2000041497A2 (fr) |
| ZA (1) | ZA200105632B (fr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1377667T3 (da) * | 2001-03-30 | 2009-03-30 | Leadd Bv | Fusionsproteiner til specifik behandling af cancer og autoimmunsygdomme |
| CN1582301A (zh) * | 2001-05-25 | 2005-02-16 | 尼莫克斯股份有限公司 | 有效治疗肿瘤和其它需要除去或破坏细胞的疾病的肽 |
| JP4587667B2 (ja) * | 2001-07-19 | 2010-11-24 | ナイモックス コーポレーション | 細胞の除去又は破壊を必要とする腫瘍及び他の状態の治療に有効なペプチド |
| US7317077B2 (en) * | 2001-11-16 | 2008-01-08 | Nymox Pharmaceutical Corporation | Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5670488A (en) * | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5981502A (en) * | 1990-09-12 | 1999-11-09 | Leadd B.V. | Methods and compositions for inducing apoptosis in tumor cells |
| EP0878546A1 (fr) * | 1997-04-15 | 1998-11-18 | Leadd B.V. | Véhicules de transfert de gènes exprimant la protéine VP2 induisant l'apoptose, et/ou l'apoptine |
| US5792751A (en) * | 1992-04-13 | 1998-08-11 | Baylor College Of Medicine | Tranformation of cells associated with fluid spaces |
| EP0830604B1 (fr) * | 1995-06-07 | 2003-05-28 | Leadd B.V. | Utilisations de l'apoptine |
| DE19704979A1 (de) * | 1996-02-07 | 1997-08-14 | Max Delbrueck Centrum | Retroviraler Vektor für den Gentransfer eines IL6-Antagonisten in humane hämatopoetische Stammzellen |
| RU2198683C2 (ru) * | 1997-02-28 | 2003-02-20 | Берингер Ингельхайм Фармасьютикельс, Инк. | Саморегулируемый апоптоз воспалительных клеток с помощью генной терапии |
| IL123756A0 (en) * | 1997-03-21 | 1998-10-30 | Sankyo Co | Humanized anti-human FAS antibody |
| JPH10324699A (ja) * | 1997-03-21 | 1998-12-08 | Sankyo Co Ltd | 抗ヒトＦａｓヒト化抗体 |
-
2000
- 2000-01-10 PT PT00900970T patent/PT1143994E/pt unknown
- 2000-01-10 MX MXPA01006998A patent/MXPA01006998A/es unknown
- 2000-01-10 AT AT00900970T patent/ATE244014T1/de not_active IP Right Cessation
- 2000-01-10 TR TR2001/02713T patent/TR200102713T2/xx unknown
- 2000-01-10 JP JP2000593120A patent/JP2003500336A/ja active Pending
- 2000-01-10 DE DE60003632T patent/DE60003632T2/de not_active Expired - Fee Related
- 2000-01-10 ES ES00900970T patent/ES2202039T3/es not_active Expired - Lifetime
- 2000-01-10 EA EA200100770A patent/EA200100770A1/ru unknown
- 2000-01-10 CA CA002359392A patent/CA2359392A1/fr not_active Abandoned
- 2000-01-10 EP EP20000900970 patent/EP1143994B1/fr not_active Expired - Lifetime
- 2000-01-10 HU HU0200552A patent/HUP0200552A2/hu unknown
- 2000-01-10 AU AU30835/00A patent/AU3083500A/en not_active Abandoned
- 2000-01-10 IL IL14422800A patent/IL144228A0/xx unknown
- 2000-01-10 WO PCT/NL2000/000013 patent/WO2000041497A2/fr active IP Right Grant
- 2000-01-10 DK DK00900970T patent/DK1143994T3/da active
-
2001
- 2001-07-09 ZA ZA200105632A patent/ZA200105632B/en unknown
- 2001-07-09 NO NO20013397A patent/NO20013397L/no not_active Application Discontinuation
- 2001-07-10 IL IL144228A patent/IL144228A/en not_active IP Right Cessation
-
2005
- 2005-02-25 US US11/067,001 patent/US20050271624A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ATE244014T1 (de) | 2003-07-15 |
| NO20013397D0 (no) | 2001-07-09 |
| DK1143994T3 (da) | 2003-10-20 |
| WO2000041497A3 (fr) | 2000-09-28 |
| AU3083500A (en) | 2000-08-01 |
| CA2359392A1 (fr) | 2000-07-20 |
| ES2202039T3 (es) | 2004-04-01 |
| PT1143994E (pt) | 2003-11-28 |
| NO20013397L (no) | 2001-09-11 |
| DE60003632D1 (de) | 2003-08-07 |
| EA200100770A1 (ru) | 2002-02-28 |
| EP1143994B1 (fr) | 2003-07-02 |
| WO2000041497A2 (fr) | 2000-07-20 |
| US20050271624A1 (en) | 2005-12-08 |
| JP2003500336A (ja) | 2003-01-07 |
| TR200102713T2 (tr) | 2002-05-21 |
| HUP0200552A2 (en) | 2002-06-29 |
| IL144228A (en) | 2009-06-15 |
| DE60003632T2 (de) | 2004-04-15 |
| EP1143994A2 (fr) | 2001-10-17 |
| ZA200105632B (en) | 2002-10-09 |
| MXPA01006998A (es) | 2002-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN08064A1 (en) | Albumin fusion proteins | |
| PT1157042E (pt) | Produção de anticorpos tetravalentes | |
| MXPA03002413A (es) | Moleculas tipo b7 y uso de las mismas. | |
| WO2003048327A3 (fr) | Anticorps anti-cd45rb s'utilisant dans le traitement de maladies auto-immunes et de rejet de greffon | |
| EP1005540A4 (fr) | Proteines ikk-beta, acides nucleiques et procedes | |
| IL123189A0 (en) | Colon cell and colon cancer cell associated nucleic acid molecules protein and peptides | |
| AU8881201A (en) | Tnf receptor-like molecules and uses thereof | |
| WO2002018620A3 (fr) | Neutrokine-alpha et variant d'epissage de neutrokine-alpha | |
| WO2003033658A3 (fr) | Neutrokine-alpha et variant d'epissage de neutrokine-alpha | |
| WO2001098491A3 (fr) | Polymorphismes genetiques d'osteolevine | |
| WO1999028461A3 (fr) | Dispositif et procede d'induction de l'apoptose en faisant interferer des proteines de type bip | |
| IL144228A0 (en) | Use of apoptosis inducing agents in the treatment of (auto) immune diseases | |
| AU2003225237A1 (en) | Antibodies that specifically bind to chemokine beta-4 | |
| IL154298A0 (en) | Papap proteins, their preparation and use | |
| MXPA03000979A (es) | Moleculas tipo receptor de complemento c3b/c4b y usos de las mismas. | |
| MXPA03010728A (es) | Moleculas de proteina-2 relacionadas con b7 y uso de las mismas. | |
| EP1161262A4 (fr) | COLLIGIN/HsP47 A LOCALISATION SUPERFICIELLE DANS LES CELLULES DES CARCINOMES | |
| WO2004020591A3 (fr) | Methodes d'utilisation de nouveaux polypeptides humains codes par des polynucleotides | |
| EP1475441A3 (fr) | Acides nucléiques et polypeptides spécifiques des souches pathogènes du genre Neisseria | |
| WO2002072632A3 (fr) | Acides nucleiques du gene abcc11 humain, vecteurs contenant lesdits acides nucleiques et leurs utilisations | |
| WO2002079222A3 (fr) | Proteines de fusion pour le traitement specifique du cancer et de maladies auto-immunes | |
| WO2002044366A3 (fr) | Nouvelles proteines humaines specifiques de la retine c7orf9, c12orf7, mpp4 et f379 | |
| WO2001061010A3 (fr) | Proteines activant la gtpase | |
| WO2002063013A3 (fr) | Nouveau gene de phosphatase acide | |
| WO2006048657A3 (fr) | Technique therapeutique |